| Year |
Citation |
Score |
| 2023 |
Abdel-Hafiz HA, Kailasam Mani SK, Huang W, Gouin KH, Chang Y, Xiao T, Ma Q, Li Z, Knott SRV, Theodorescu D. Single-cell profiling of murine bladder cancer identifies sex-specific transcriptional signatures with prognostic relevance. Iscience. 26: 107703. PMID 37701814 DOI: 10.1016/j.isci.2023.107703 |
0.319 |
|
| 2023 |
Abdel-Hafiz HA, Schafer JM, Chen X, Xiao T, Gauntner TD, Li Z, Theodorescu D. Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature. PMID 37344596 DOI: 10.1038/s41586-023-06234-x |
0.328 |
|
| 2023 |
Castaneda PR, Theodorescu D, Rosser CJ, Ahdoot M. Identifying novel biomarkers associated with bladder cancer treatment outcomes. Frontiers in Oncology. 13: 1114203. PMID 37064102 DOI: 10.3389/fonc.2023.1114203 |
0.345 |
|
| 2023 |
Bhowmick N, Posadas E, Ellis L, Freedland SJ, Vizio DD, Freeman MR, Theodorescu D, Figlin R, Gong J. Targeting Glutamine Metabolism in Prostate Cancer. Frontiers in Bioscience (Elite Edition). 15: 2. PMID 36959101 DOI: 10.31083/j.fbe1501002 |
0.317 |
|
| 2022 |
Agarwal N, Zhou Q, Arya D, Rinaldetti S, Duex J, LaBarbera DV, Theodorescu D. AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer. International Journal of Molecular Sciences. 23. PMID 36142729 DOI: 10.3390/ijms231810819 |
0.34 |
|
| 2022 |
Schafer JM, Xiao T, Kwon H, Collier K, Chang Y, Abdel-Hafiz H, Bolyard C, Chung D, Yang Y, Sundi D, Ma Q, Theodorescu D, Li X, Li Z. Sex-biased adaptive immune regulation in cancer development and therapy. Iscience. 25: 104717. PMID 35880048 DOI: 10.1016/j.isci.2022.104717 |
0.311 |
|
| 2022 |
Lee YC, Lam HM, Rosser C, Theodorescu D, Parks WC, Chan KS. The dynamic roles of the bladder tumour microenvironment. Nature Reviews. Urology. PMID 35764795 DOI: 10.1038/s41585-022-00608-y |
0.328 |
|
| 2022 |
Zhang Y, Huo F, Cao Q, Jia R, Huang Q, Wang ZA, Theodorescu D, Lv Q, Li P, Yan C. FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer. Journal For Immunotherapy of Cancer. 10. PMID 35361729 DOI: 10.1136/jitc-2021-003939 |
0.344 |
|
| 2022 |
Nikolos F, Hayashi K, Hoi XP, Alonzo ME, Mo Q, Kasabyan A, Furuya H, Trepel J, Di Vizio D, Guarnerio J, Theodorescu D, Rosser C, Apolo A, Galsky M, Chan KS. Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nature Communications. 13: 1487. PMID 35347124 DOI: 10.1038/s41467-022-29026-9 |
0.306 |
|
| 2022 |
Wang Y, Zhang Y, Li PC, Guo J, Huo F, Yang J, Jia R, Wang J, Huang Q, Theodorescu D, Yu H, Yan C. Development of novel aptamer-based targeted chemotherapy for bladder cancer. Cancer Research. PMID 35064018 DOI: 10.1158/0008-5472.CAN-21-2691 |
0.372 |
|
| 2021 |
Xiao JF, Caliri AW, Duex JE, Theodorescu D. Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. Cancers. 13. PMID 34638374 DOI: 10.3390/cancers13194891 |
0.369 |
|
| 2021 |
Gouin KH, Ing N, Plummer JT, Rosser CJ, Ben Cheikh B, Oh C, Chen SS, Chan KS, Furuya H, Tourtellotte WG, Knott SRV, Theodorescu D. An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. Nature Communications. 12: 4906. PMID 34385456 DOI: 10.1038/s41467-021-25103-7 |
0.369 |
|
| 2021 |
Ahdoot M, Theodorescu D. Immunotherapy of high risk non-muscle invasive bladder cancer. Expert Review of Clinical Pharmacology. PMID 34187272 DOI: 10.1080/17512433.2021.1950531 |
0.309 |
|
| 2021 |
Sottnik JL, Vanderlinden LA, Joshi M, Chauca-Diaz A, Owens C, Hansel DE, Sempeck C, Ghosh D, Theodorescu D. Androgen Receptor Regulates CD44 Expression in Bladder Cancer. Cancer Research. PMID 33687952 DOI: 10.1158/0008-5472.CAN-20-3095 |
0.353 |
|
| 2020 |
Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nature Reviews. Cancer. PMID 33268841 DOI: 10.1038/s41568-020-00313-1 |
0.377 |
|
| 2020 |
Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S, Lee JG, Cogdell D, Zhang M, Yang G, Dadhania V, Choi W, Wei P, Gao J, Theodorescu D, et al. Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Scientific Reports. 10: 9743. PMID 32546765 DOI: 10.1038/S41598-020-66747-7 |
0.373 |
|
| 2020 |
Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S, Lee JG, Zhang S, Choi W, Wang Y, Liang Y, Wang G, Wang Y, Yao H, Dadhania V, Gao J, ... Theodorescu D, et al. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. Iscience. 23: 101201. PMID 32521509 DOI: 10.1016/J.Isci.2020.101201 |
0.324 |
|
| 2020 |
Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, ... ... Theodorescu D, et al. Abstract IA10: Developing rational combination therapy with checkpoint inhibitors Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Bladder19-Ia10 |
0.366 |
|
| 2019 |
Sheta EA, Harding MA, Conaway MR, Theodorescu D. Transformation dependent signalling pathways leading to transcriptional induction of vascular endothelial growth factor in prostate cancer. Prostate Cancer and Prostatic Diseases. 3: S39. PMID 12497147 DOI: 10.1038/Sj.Pcan.4500465 |
0.354 |
|
| 2019 |
Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality of life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Prostate Cancer and Prostatic Diseases. 2: S32. PMID 12496811 DOI: 10.1038/Sj.Pcan.4500357 |
0.36 |
|
| 2019 |
Jones RT, Zuiverloon TC, Vekony H, Goodspeed A, Laajala TD, Joshi M, Sempeck C, Tu M, Costello JC, Theodorescu D. Abstract 2107: Integrative molecular and functional genomic analysis of chemotherapy resistant bladder cancer cell lines identifies novel mediators of therapeutic response Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2107 |
0.379 |
|
| 2019 |
Tu MM, Lee FY, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, ... ... Theodorescu D, et al. Abstract 4085: DDR2 inhibition enhances response to anti-PD-1 immunotherapy Cancer Research. 79: 4085-4085. DOI: 10.1158/1538-7445.Am2019-4085 |
0.317 |
|
| 2019 |
Jong FCd, Zuiverloon TCM, Theodorescu D. Precision Medicine in Bladder Cancer Oncology Times Uk. 41: 1. DOI: 10.1097/01.Cot.0000560020.32940.E1 |
0.441 |
|
| 2018 |
Sottnik JL, Mallaredy V, Chauca-Diaz A, Ritterson Lew C, Owens C, Dancik GM, Pagliarani S, Lucchiari S, Moggio M, Ripolone M, Comi GP, Frierson HF, Clouthier D, Theodorescu D. Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice. Carcinogenesis. PMID 30403777 DOI: 10.1093/Carcin/Bgy139 |
0.337 |
|
| 2018 |
Morgan MJ, Fitzwalter BE, Owens CR, Powers RK, Sottnik JL, Gamez G, Costello JC, Theodorescu D, Thorburn A. Metastatic cells are preferentially vulnerable to lysosomal inhibition. Proceedings of the National Academy of Sciences of the United States of America. PMID 30127018 DOI: 10.1073/Pnas.1706526115 |
0.4 |
|
| 2018 |
Goodspeed A, Jean A, Theodorescu D, Costello JC. A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition. Bladder Cancer (Amsterdam, Netherlands). 4: 269-282. PMID 30112438 DOI: 10.3233/BLC-170161 |
0.383 |
|
| 2018 |
Richmond CS, Oldenburg D, Dancik G, Meier DR, Weinhaus B, Theodorescu D, Guin S. Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth. Oncotarget. 9: 16718-16730. PMID 29682180 DOI: 10.18632/Oncotarget.24676 |
0.38 |
|
| 2018 |
Jones RT, Theodorescu D. Two methods of prediction signatures. Nature Reviews. Urology. PMID 29581570 DOI: 10.1038/S41585-018-0004-2 |
0.389 |
|
| 2018 |
Fantini D, Glaser AP, Rimar KJ, Wang Y, Schipma M, Varghese N, Rademaker A, Behdad A, Yellapa A, Yu Y, Sze CC, Wang L, Zhao Z, Crawford SE, Hu D, ... Theodorescu D, et al. A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene. PMID 29367767 DOI: 10.1038/S41388-017-0099-6 |
0.387 |
|
| 2018 |
Yan C, Theodorescu D. RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer. Pharmacological Reviews. 70: 1-11. PMID 29196555 DOI: 10.1124/Pr.117.014415 |
0.364 |
|
| 2017 |
Agarwal N, Theodorescu D. The Role of Transcription Factor YY1 in the Biology of Cancer. Critical Reviews in Oncogenesis. 22: 13-21. PMID 29604933 DOI: 10.1615/Critrevoncog.2017021071 |
0.398 |
|
| 2017 |
Felsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nature Reviews. Urology. PMID 29133939 DOI: 10.1038/Nrurol.2017.179 |
0.464 |
|
| 2017 |
Duex JE, Swain KE, Dancik GM, Paucek RD, Owens C, Churchill MEA, Theodorescu D. Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. Molecular Cancer Research : McR. PMID 28970362 DOI: 10.1158/1541-7786.Mcr-17-0260 |
0.343 |
|
| 2017 |
Zuiverloon TC, Theodorescu D. Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. Pharmacogenomics. PMID 28745580 DOI: 10.2217/Pgs-2017-0055 |
0.394 |
|
| 2017 |
Duex JE, Owens C, Chauca-Diaz A, Dancik GM, Vanderlinden LA, Ghosh D, Leivo MZ, Hansel DE, Theodorescu D. Nuclear CD24 drives tumor growth and is predictive of poor patient prognosis. Cancer Research. PMID 28674079 DOI: 10.1158/0008-5472.Can-17-0367 |
0.412 |
|
| 2017 |
Theodorescu D. Abstract SY36-01: Optimizing neoadjuvant therapy prior to surgery: Biomarker and target discovery Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Sy36-01 |
0.496 |
|
| 2017 |
Kim S, Varticovski L, Lao Q, Baek S, Nickerson ML, Sung M, Grontved L, Bethtrice T, Theodorescu D, Agarwal PK, Dean M, Hager G. Abstract 3352: Genome-wide enhancer identify signature predictive of metastatic phenotypes in bladder cancers Cancer Research. 77: 3352-3352. DOI: 10.1158/1538-7445.Am2017-3352 |
0.401 |
|
| 2016 |
Oldenburg D, Ru Y, Weinhaus B, Cash S, Theodorescu D, Guin S. CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL). Bmc Cancer. 16: 713. PMID 27595989 DOI: 10.1186/S12885-016-2756-5 |
0.388 |
|
| 2016 |
Ahmed M, Sottnik JL, Dancik GM, Sahu D, Hansel DE, Theodorescu D, Schwartz MA. An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. Cancer Cell. PMID 27593345 DOI: 10.1016/J.Ccell.2016.08.002 |
0.416 |
|
| 2016 |
Agarwal N, Dancik GM, Goodspeed A, Costello JC, Owens C, Duex JE, Theodorescu D. GON4L drives cancer growth through a YY1- androgen receptor-CD24 axis. Cancer Research. PMID 27312530 DOI: 10.1158/0008-5472.Can-16-1099 |
0.456 |
|
| 2016 |
Nickerson ML, Witte N, Im KM, Turan S, Owens C, Misner K, Tsang SX, Cai Z, Wu S, Dean M, Costello JC, Theodorescu D. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene. PMID 27270441 DOI: 10.1038/Onc.2016.172 |
0.434 |
|
| 2016 |
Frantzi M, Van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, ... Theodorescu D, et al. Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27026199 DOI: 10.1158/1078-0432.Ccr-15-2715 |
0.43 |
|
| 2016 |
Jones RT, Felsenstein KM, Theodorescu D. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer. The Urologic Clinics of North America. 43: 77-86. PMID 26614030 DOI: 10.1016/J.Ucl.2015.08.007 |
0.393 |
|
| 2016 |
Nickerson M, Im KM, Guo G, Gui Y, Turan S, Costello JC, Zhou Q, Cai Z, Wu S, Lucia MS, Moore LE, Dean M, Theodorescu D. Abstract A52: Gene alterations associated with clinical characteristics of bladder cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-A52 |
0.426 |
|
| 2016 |
Duex J, Lee C, Owens C, Chauca-Diaz A, Theodorescu D. Abstract 1140: CD24 exists in the nucleus and drives cancer growth Cancer Research. 76: 1140-1140. DOI: 10.1158/1538-7445.Am2016-1140 |
0.378 |
|
| 2015 |
Dancik GM, Theodorescu D. The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer. Bladder Cancer (Amsterdam, Netherlands). 1: 45-63. PMID 30561442 DOI: 10.3233/BLC-150012 |
0.347 |
|
| 2015 |
Gustafson DL, Fowles JS, Brown KC, Theodorescu D. Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy. Assay and Drug Development Technologies. 13: 623-7. PMID 26690765 DOI: 10.1089/Adt.2015.29012.Dlgdrrr |
0.373 |
|
| 2015 |
Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, et al. Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies. Bmc Genomics. 16: 1019. PMID 26621286 DOI: 10.1186/S12864-015-2227-4 |
0.324 |
|
| 2015 |
Stern JL, Theodorescu D, Vogelstein B, Papadopoulos N, Cech TR. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes & Development. 29: 2219-24. PMID 26515115 DOI: 10.1101/Gad.269498.115 |
0.346 |
|
| 2015 |
Guin S, Ru Y, Agarwal N, Lew CR, Owens C, Comi GP, Theodorescu D. Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26490312 DOI: 10.1158/1078-0432.Ccr-15-1706 |
0.367 |
|
| 2015 |
Yan C, Jones DN, Theodorescu D. Drugging the Ral GTPase. Small Gtpases. 6: 157-9. PMID 26280620 DOI: 10.1080/21541248.2015.1018403 |
0.394 |
|
| 2015 |
Hensel J, Duex JE, Owens C, Dancik GM, Edwards MG, Frierson HF, Theodorescu D. Patient mutation directed shRNA screen uncovers novel bladder tumor growth suppressors. Molecular Cancer Research : McR. PMID 26078295 DOI: 10.1158/1541-7786.Mcr-15-0130 |
0.462 |
|
| 2015 |
Ritterson Lew C, Guin S, Theodorescu D. Targeting glycogen metabolism in bladder cancer. Nature Reviews. Urology. 12: 383-91. PMID 26032551 DOI: 10.1038/Nrurol.2015.111 |
0.462 |
|
| 2015 |
Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. Bmc Genomics. 16: 403. PMID 25997541 DOI: 10.1186/S12864-015-1450-3 |
0.431 |
|
| 2015 |
Apolo AB, Vogelzang NJ, Theodorescu D. New and promising strategies in the management of bladder cancer. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 105-12. PMID 25993148 DOI: 10.14694/EdBook_AM.2015.35.105 |
0.355 |
|
| 2015 |
Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D, Cech TR. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science (New York, N.Y.). 347: 1006-10. PMID 25722414 DOI: 10.1126/Science.1260200 |
0.416 |
|
| 2015 |
Zhao D, Besser AH, Wander SA, Sun J, Zhou W, Wang B, Ince T, Durante MA, Guo W, Mills G, Theodorescu D, Slingerland J. Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene. PMID 25684140 DOI: 10.1038/Onc.2014.473 |
0.353 |
|
| 2015 |
Guin S, Theodorescu D. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer. Acta Pharmacologica Sinica. 36: 291-7. PMID 25557115 DOI: 10.1038/Aps.2014.129 |
0.356 |
|
| 2015 |
Griner EM, Dancik GM, Costello JC, Owens C, Guin S, Edwards MG, Brautigan DL, Theodorescu D. RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Molecular Cancer Research : McR. 13: 483-92. PMID 25516960 DOI: 10.1158/1541-7786.Mcr-14-0420 |
0.491 |
|
| 2015 |
Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, et al. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urologic Oncology. 33: 53-64. PMID 25065704 DOI: 10.1016/J.Urolonc.2014.06.013 |
0.396 |
|
| 2015 |
Kothari S, Gustafson D, Killian K, Costello J, Edelman DC, Walling J, Meltzer PS, Theodorescu D, Apolo AB. COXEN prediction of antineoplastic drug sensitivity in bladder cancer patients. Journal of Clinical Oncology. 33: 365-365. DOI: 10.1200/Jco.2016.34.2_Suppl.365 |
0.414 |
|
| 2015 |
Nickerson ML, Im KM, Turan S, Guo G, Moore LE, Theodorescu D, Dean M. Abstract A1-01: Translational genomics of urologic cancer genes Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A1-01 |
0.456 |
|
| 2015 |
Guin S, Ru Y, Lew CR, Agarwal N, Owens C, Theodorescu D. Abstract 4949: HAS2 is a critical effector for AGL mediated regulation of tumor growth Cancer Research. 75: 4949-4949. DOI: 10.1158/1538-7445.Am2015-4949 |
0.506 |
|
| 2015 |
Varticovski L, Kim S, Nickerson ML, Thompson B, Lao Q, Grøntved L, Baek S, Sung M, Theodorescu D, Dean M, Hager GL. Abstract 4783: Novel molecular markers of bladder cancer progression identified by global chromatin profiling Cancer Research. 75: 4783-4783. DOI: 10.1158/1538-7445.Am2015-4783 |
0.491 |
|
| 2015 |
Kim S, Varticovski L, Lao Q, Baek S, Sung M, Grøntved L, Nickerson ML, Thompson B, Theodorescu D, Dean M, Hager GH. Abstract 4782: Genome-wide chromatin profiling in bladder and prostate cancers Cancer Research. 75: 4782-4782. DOI: 10.1158/1538-7445.Am2015-4782 |
0.488 |
|
| 2015 |
Nickerson ML, Im KM, Turan S, Moore LE, Dean M, Theodorescu D. Abstract 1105: Clinical associations between altered bladder cancer genes Cancer Research. 75: 1105-1105. DOI: 10.1158/1538-7445.Am2015-1105 |
0.466 |
|
| 2015 |
Lew CR, Guin S, Theodorescu D. Targeting glycogen metabolism in bladder cancer Nature Reviews Urology. 12: 383-391. DOI: 10.1038/nrurol.2015.111 |
0.358 |
|
| 2014 |
Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urologic Oncology. 32: 1108-15. PMID 25443274 DOI: 10.1016/J.Urolonc.2013.10.021 |
0.409 |
|
| 2014 |
Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, Hendrix A, Lamy P, Dagnaes-Hansen F, Rasmussen MH, Bui KH, Fristrup N, Christensen EI, Nordentoft I, Morth JP, ... ... Theodorescu D, et al. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Research. 74: 5758-71. PMID 25261234 DOI: 10.1158/0008-5472.Can-13-3512 |
0.357 |
|
| 2014 |
Nickerson ML, Dancik GM, Im KM, Edwards MG, Turan S, Brown J, Ruiz-Rodriguez C, Owens C, Costello JC, Guo G, Tsang SX, Li Y, Zhou Q, Cai Z, Moore LE, ... ... Theodorescu D, et al. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4935-48. PMID 25225064 DOI: 10.1158/1078-0432.Ccr-14-0330 |
0.391 |
|
| 2014 |
Yan C, Liu D, Li L, Wempe MF, Guin S, Khanna M, Meier J, Hoffman B, Owens C, Wysoczynski CL, Nitz MD, Knabe WE, Ahmed M, Brautigan DL, Paschal BM, ... ... Theodorescu D, et al. Discovery and characterization of small molecules that target the GTPase Ral. Nature. 515: 443-7. PMID 25219851 DOI: 10.1038/Nature13713 |
0.371 |
|
| 2014 |
Costello JC, Theodorescu D. Decade in review-bladder cancer: international progress: from cytology to genomics. Nature Reviews. Urology. 11: 609-10. PMID 25179501 DOI: 10.1038/Nrurol.2014.236 |
0.38 |
|
| 2014 |
Hussain M, Theodorescu D. Bladder cancer: bladder preservation--learning what we don't know. Nature Reviews. Urology. 11: 310-2. PMID 24841166 DOI: 10.1038/Nrurol.2014.102 |
0.383 |
|
| 2014 |
Guin S, Pollard C, Ru Y, Ritterson Lew C, Duex JE, Dancik G, Owens C, Spencer A, Knight S, Holemon H, Gupta S, Hansel D, Hellerstein M, Lorkiewicz P, Lane AN, ... ... Theodorescu D, et al. Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. Journal of the National Cancer Institute. 106. PMID 24700805 DOI: 10.1093/Jnci/Dju062 |
0.393 |
|
| 2014 |
Kaur S, Momi N, Chakraborty S, Wagner DG, Horn AJ, Lele SM, Theodorescu D, Batra SK. Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis. Plos One. 9: e92742. PMID 24671186 DOI: 10.1371/Journal.Pone.0092742 |
0.363 |
|
| 2014 |
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, ... Theodorescu D, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine. 6: 224ra24. PMID 24553385 DOI: 10.1126/Scitranslmed.3007094 |
0.478 |
|
| 2014 |
Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, Diamond JR. Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. Plos One. 9: e86532. PMID 24505259 DOI: 10.1371/Journal.Pone.0086532 |
0.342 |
|
| 2014 |
Dancik GM, Theodorescu D. Robust prognostic gene expression signatures in bladder cancer and lung adenocarcinoma depend on cell cycle related genes. Plos One. 9: e85249. PMID 24465512 DOI: 10.1371/Journal.Pone.0085249 |
0.408 |
|
| 2014 |
Dancik GM, Theodorescu D. Pharmacogenomics in bladder cancer. Urologic Oncology. 32: 16-22. PMID 24360659 DOI: 10.1016/J.Urolonc.2013.09.007 |
0.428 |
|
| 2014 |
Dancik GM, Owens CR, Iczkowski KA, Theodorescu D. A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells (Dayton, Ohio). 32: 974-82. PMID 24357085 DOI: 10.1002/Stem.1625 |
0.484 |
|
| 2014 |
Solomon DA, Kim J, Bondaruk J, Shariat SF, Wang Z, Elkahloun A, Gerard J, Zhuang D, Zhang S, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Kuefer R, Netto GJ, ... Theodorescu D, et al. Frequent truncating mutations of the cohesin complex gene STAG2 in urothelial carcinoma of the bladder. Journal of Clinical Oncology. 32: 290-290. DOI: 10.1200/Jco.2014.32.4_Suppl.290 |
0.404 |
|
| 2014 |
Varticovski L, Kim S, Nickerson M, Grontved L, Lao Q, Thompson B, Theodorescu D, Hager G. Bladder cancer global unbiased chromatin landscape characterization by DHS-seq to identify novel features unique for each stage of progression. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E15500 |
0.452 |
|
| 2013 |
Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 1492-501. PMID 24389431 DOI: 10.1097/Jto.0000000000000007 |
0.356 |
|
| 2013 |
Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, Yang Z, Li X, Song P, Zhao X, ... Theodorescu D, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nature Genetics. 45: 1459-63. PMID 24121792 DOI: 10.1038/Ng.2798 |
0.412 |
|
| 2013 |
Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, ... Theodorescu D, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics. 45: 1428-30. PMID 24121789 DOI: 10.1038/Ng.2800 |
0.418 |
|
| 2013 |
Wang H, Ru Y, Sanchez-Carbayo M, Wang X, Kieft JS, Theodorescu D. Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2850-60. PMID 23575475 DOI: 10.1158/1078-0432.Ccr-12-3084 |
0.482 |
|
| 2013 |
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, ... ... Theodorescu D, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 110: 6021-6. PMID 23530248 DOI: 10.1093/Neuonc/Nou206.18 |
0.341 |
|
| 2013 |
Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA, Theodorescu D. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. The Journal of Clinical Investigation. 123: 751-66. PMID 23321672 DOI: 10.1172/Jci64782 |
0.458 |
|
| 2013 |
Grau L, Luque-Garcia JL, González-Peramato P, Theodorescu D, Palou J, Fernandez-Gomez JM, Sánchez-Carbayo M. A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness. Plos One. 8: e53328. PMID 23308193 DOI: 10.1371/Journal.Pone.0053328 |
0.468 |
|
| 2013 |
Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy. Nature Reviews. Clinical Oncology. 10: 41-51. PMID 23183631 DOI: 10.1038/Nrclinonc.2012.207 |
0.436 |
|
| 2013 |
Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. European Urology. 63: 58-66. PMID 22917984 DOI: 10.1016/J.Eururo.2012.08.010 |
0.442 |
|
| 2013 |
Griner EM, Churchill ME, Brautigan DL, Theodorescu D. PKCα phosphorylation of RhoGDI2 at Ser31 disrupts interactions with Rac1 and decreases GDI activity. Oncogene. 32: 1010-7. PMID 22469974 DOI: 10.1038/Onc.2012.124 |
0.333 |
|
| 2013 |
Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA, Theodorescu D. Loss of SPARC in bladder cancer enhances carcinogenesis and progression (Journal of Clinical Investigation (2013) 123, 2 (751-766) DOI: 10.1172/JCI64782) Journal of Clinical Investigation. 123: 4089. DOI: 10.1172/Jci71241 |
0.424 |
|
| 2013 |
Ru Y, Kechris KJ, Smith SC, Calin GA, Theodorescu D. Abstract 2899: Significance of microRNA:target interaction in bladder cancer metastasis. Cancer Research. 73: 2899-2899. DOI: 10.1158/1538-7445.Am2013-2899 |
0.338 |
|
| 2013 |
Dancik G, Theodorescu D. Abstract 2379: The importance of cell cycle biomarkers in prognostic signatures in tobacco-related cancers. Cancer Research. 73: 2379-2379. DOI: 10.1158/1538-7445.Am2013-2379 |
0.414 |
|
| 2012 |
Said N, Theodorescu D. RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment. Oncoimmunology. 1: 1175-1177. PMID 23170270 DOI: 10.4161/Onci.20594 |
0.441 |
|
| 2012 |
Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD, Harding MA, Smith SC, Frierson HF, Conaway M, Theodorescu D. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proceedings of the National Academy of Sciences of the United States of America. 109: E3588-96. PMID 23012401 DOI: 10.1073/Pnas.1113960109 |
0.655 |
|
| 2012 |
Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M, Ørntoft TF, Dyrskjøt L. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. Bmc Medical Genomics. 5: 40. PMID 22954303 DOI: 10.1186/1755-8794-5-40 |
0.357 |
|
| 2012 |
Thomas S, Harding MA, Smith SC, Overdevest JB, Nitz MD, Frierson HF, Tomlins SA, Kristiansen G, Theodorescu D. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Research. 72: 5600-12. PMID 22926560 DOI: 10.1158/0008-5472.Can-11-3666 |
0.664 |
|
| 2012 |
Said N, Theodorescu D. Permissive role of endothelin receptors in tumor metastasis. Life Sciences. 91: 522-7. PMID 22846215 DOI: 10.1016/J.Lfs.2012.03.040 |
0.413 |
|
| 2012 |
Griner EM, Theodorescu D. The faces and friends of RhoGDI2. Cancer Metastasis Reviews. 31: 519-28. PMID 22718398 DOI: 10.1007/S10555-012-9376-6 |
0.424 |
|
| 2012 |
Flaig TW, Theodorescu D. Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. European Urology. 62: 183-4. PMID 22640860 DOI: 10.1016/J.Eururo.2012.04.014 |
0.354 |
|
| 2012 |
DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, et al. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. Plos One. 7: e36669. PMID 22590586 DOI: 10.1371/Journal.Pone.0036669 |
0.5 |
|
| 2012 |
Smith SC, Baras AS, Owens CR, Dancik G, Theodorescu D. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Research. 72: 3480-91. PMID 22586063 DOI: 10.1158/0008-5472.Can-11-3966 |
0.521 |
|
| 2012 |
Dancika GM, Theodorescu D. Perspectives on personalized cancer care. Urologic Oncology. 30: 121-5. PMID 22489325 DOI: 10.1016/J.Urolonc.2011.01.004 |
0.332 |
|
| 2012 |
Said N, Sanchez-Carbayo M, Smith SC, Theodorescu D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. The Journal of Clinical Investigation. 122: 1503-18. PMID 22406535 DOI: 10.1172/Jci61392 |
0.476 |
|
| 2012 |
Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D, Lee JK. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. Plos One. 7: e30550. PMID 22348014 DOI: 10.1371/Journal.Pone.0030550 |
0.406 |
|
| 2012 |
Flaig TW, Theodorescu D. Bladder cancer in 2011: the dawn of personalized medicine. Nature Reviews. Urology. 9: 65-6. PMID 22187014 DOI: 10.1038/Nrurol.2011.220 |
0.384 |
|
| 2012 |
Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. Journal of Immunology (Baltimore, Md. : 1950). 188: 198-205. PMID 22116822 DOI: 10.4049/Jimmunol.1101845 |
0.345 |
|
| 2012 |
Wang H, Wang X, Ru Y, Conaway MR, Kieft JS, Theodorescu D. Abstract 4200: Translation initiation factor eIF3b expression and its role in cancer cell growth and metastases Cancer Research. 72: 4200-4200. DOI: 10.1158/1538-7445.Am2012-4200 |
0.494 |
|
| 2012 |
Ru Y, Kechris KJ, Smith SC, Calin GA, Theodorescu D. Abstract 3391: Interaction of microRNAs and target genes in bladder cancer metastasis Cancer Research. 72: 3391-3391. DOI: 10.1158/1538-7445.Am2012-3391 |
0.317 |
|
| 2012 |
Ostenfeld MS, Jeppesen D, Morth JP, Khanh HB, Theodorescu D, Borre M, Dyrskjøt L, Ørntoft T. Abstract 3387: Secreted exosomes from cultured bladder cells are enriched for distinct miRNAs detected in circulation of metastatic bladder cancer patients Cancer Research. 72: 3387-3387. DOI: 10.1158/1538-7445.Am2012-3387 |
0.355 |
|
| 2012 |
Dancik GM, Theodorescu D. Abstract 2996: The prognostic value of a cell cycle proliferation gene signature in bladder cancer Cancer Research. 72: 2996-2996. DOI: 10.1158/1538-7445.Am2012-2996 |
0.433 |
|
| 2012 |
Guin S, Ru Y, Mishra R, Vasu VT, Owens C, Finigan JH, Kern JA, Theodorescu D. Abstract 2138: Tumorigenic and migratory potential of Ral GTPases in non-small cell lung cancers Cancer Research. 72: 2138-2138. DOI: 10.1158/1538-7445.Am2012-2138 |
0.42 |
|
| 2011 |
Williams PD, Owens CR, Dziegielewski J, Moskaluk CA, Read PW, Larner JM, Story MD, Brock WA, Amundson SA, Lee JK, Theodorescu D. Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy. Neoplasia (New York, N.Y.). 13: 1122-31. PMID 22241958 DOI: 10.1593/Neo.111398 |
0.433 |
|
| 2011 |
Dancik GM, Ru Y, Owens CR, Theodorescu D. A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Research. 71: 7398-409. PMID 22012889 DOI: 10.1158/0008-5472.Can-11-2427 |
0.447 |
|
| 2011 |
Dancik G, Aisner D, Theodorescu D. A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. Plos Currents. 3: RRN1248. PMID 21858252 DOI: 10.1371/Currents.Rrn1248 |
0.414 |
|
| 2011 |
Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, Jia W, Chen J, ... Theodorescu D, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genetics. 43: 875-8. PMID 21822268 DOI: 10.1038/Ng.907 |
0.418 |
|
| 2011 |
Ru Y, Dancik GM, Theodorescu D. Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Current Opinion in Urology. 21: 420-7. PMID 21814055 DOI: 10.1097/Mou.0B013E32834956D6 |
0.437 |
|
| 2011 |
Nitz MD, Harding MA, Smith SC, Thomas S, Theodorescu D. RREB1 transcription factor splice variants in urologic cancer. The American Journal of Pathology. 179: 477-86. PMID 21703425 DOI: 10.1016/J.Ajpath.2011.03.038 |
0.497 |
|
| 2011 |
Aisner DL, Theodorescu D. Genetic testing for metastasis: potential for improved cancer treatment. Future Oncology (London, England). 7: 697-701. PMID 21675831 DOI: 10.2217/Fon.11.48 |
0.371 |
|
| 2011 |
Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Research. 71: 3802-11. PMID 21482678 DOI: 10.1158/0008-5472.Can-11-0519 |
0.696 |
|
| 2011 |
Jerde TJ, Wu Z, Theodorescu D, Bushman W. Regulation of phosphatase homologue of tensin protein expression by bone morphogenetic proteins in prostate epithelial cells. The Prostate. 71: 791-800. PMID 21456062 DOI: 10.1002/Pros.21295 |
0.364 |
|
| 2011 |
Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, Fradet Y, Lehmann J, Stöckle M, Hartmann A, Lee JK, Theodorescu D. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. The Lancet. Oncology. 12: 137-43. PMID 21256081 DOI: 10.1016/S1470-2045(10)70296-5 |
0.396 |
|
| 2011 |
Smith SC, Havaleshko DM, Moon K, Baras AS, Lee J, Bekiranov S, Burke DJ, Theodorescu D. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia (New York, N.Y.). 13: 72-80. PMID 21253455 DOI: 10.1593/Neo.101214 |
0.452 |
|
| 2011 |
Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. The Journal of Clinical Investigation. 121: 132-47. PMID 21183790 DOI: 10.1172/Jci42912 |
0.42 |
|
| 2011 |
Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA, Theodorescu D. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Research. 71: 832-41. PMID 21148751 DOI: 10.1158/0008-5472.Can-10-0730 |
0.714 |
|
| 2011 |
Ehdaie B, Theodorescu D. Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis. Indian Journal of Urology : Iju : Journal of the Urological Society of India. 24: 61-7. PMID 19468362 DOI: 10.4103/0970-1591.38606 |
0.345 |
|
| 2011 |
Said NA, Frierson H, Theodorescu D. Abstract 913: Differential roles of SPARC in bladder carcinogenesis and metastasis Cancer Research. 71: 913-913. DOI: 10.1158/1538-7445.Am2011-913 |
0.324 |
|
| 2011 |
Williams A, Hahn N, Galsky M, Theodorescu D, Datar R, Tai Y, Cote R. Abstract 5254: RNA extraction and gene expression profiling in circulating tumor cells (CTC) using a sized-based method for CTC capture Cancer Research. 71: 5254-5254. DOI: 10.1158/1538-7445.Am2011-5254 |
0.365 |
|
| 2011 |
Smith SC, Theodorescu D. Abstract 50: An informatic approach to rational selection of cell lines modeling complex clinicopathologic phenotypes based on gene expression: The COXEN algorithm Cancer Research. 71: 50-50. DOI: 10.1158/1538-7445.Am2011-50 |
0.448 |
|
| 2011 |
Grau L, Luque-García JL, González-Peramato P, Theodorescu D, Gil M, Palou J, Bellmunt J, Sanchez-Carbayo M. Abstract 287: A SILAC proteomics analysis to identify bladder cancer metastasis-associated candidates Cancer Research. 71: 287-287. DOI: 10.1158/1538-7445.Am2011-287 |
0.442 |
|
| 2011 |
Cheru L, Burdick M, Mason M, Theodorescu D, Krupski T, Strieter R. 1357 BCG BLADDER TUMOR SUPPRESSION IS MEDIATED BY CXCR3 Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1179 |
0.326 |
|
| 2010 |
Maroni P, Theodorescu D. Words of wisdom. Re: mortality results from the Göteborg randomised population-based prostate-cancer screening trial. European Urology. 58: 938-9. PMID 21414863 DOI: 10.1016/J.Eururo.2010.09.017 |
0.336 |
|
| 2010 |
Wu Z, Owens C, Chandra N, Popovic K, Conaway M, Theodorescu D. RalBP1 is necessary for metastasis of human cancer cell lines. Neoplasia (New York, N.Y.). 12: 1003-12. PMID 21170262 DOI: 10.1593/Neo.101080 |
0.486 |
|
| 2010 |
Krupski TL, Stukenborg GJ, Moon K, Theodorescu D. The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. Bju International. 106: 1477-83. PMID 20977594 DOI: 10.1111/J.1464-410X.2010.09356.X |
0.38 |
|
| 2010 |
Wang H, Owens C, Chandra N, Conaway MR, Brautigan DL, Theodorescu D. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Research. 70: 8760-9. PMID 20940393 DOI: 10.1158/0008-5472.Can-10-0952 |
0.358 |
|
| 2010 |
Harding MA, Theodorescu D. RhoGDI signaling provides targets for cancer therapy. European Journal of Cancer (Oxford, England : 1990). 46: 1252-9. PMID 20347589 DOI: 10.1016/J.Ejca.2010.02.025 |
0.451 |
|
| 2010 |
Pollard C, Smith SC, Theodorescu D. Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Reviews in Molecular Medicine. 12: e10. PMID 20334706 DOI: 10.1017/S1462399410001407 |
0.349 |
|
| 2010 |
Smith SC, Baras AS, Lee JK, Theodorescu D. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Research. 70: 1753-8. PMID 20160033 DOI: 10.1158/0008-5472.Can-09-3562 |
0.418 |
|
| 2010 |
Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, Baggerly K, Rouzier R, Pusztai L. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 711-8. PMID 20068086 DOI: 10.1158/1078-0432.Ccr-09-2247 |
0.345 |
|
| 2010 |
Theodorescu D. IL10 Personalized Medicine and Drug Discovery in Urological Cancer The Japanese Journal of Urology. 101: 59. DOI: 10.5980/Jpnjurol.101.59 |
0.307 |
|
| 2010 |
Ferriss JS, Kim Y, Theodorescu D, Duska LR, Lee J. A gene expression algorithm for the prediction of platinum sensitivity in ovarian cancer. Journal of Clinical Oncology. 28: 5021-5021. DOI: 10.1200/Jco.2010.28.15_Suppl.5021 |
0.402 |
|
| 2010 |
Smith SC, Havaleshko D, Moon K, Baras AS, Bekiranov S, Burke DJ, Lee JK, Theodorescu D. Abstract 747: Development and evaluation of rational combination therapy with imidazoacridinones for human bladder cancer patients through the COXEN algorithm Cancer Research. 70: 747-747. DOI: 10.1158/1538-7445.Am10-747 |
0.466 |
|
| 2010 |
Thomas S, Overdevest JB, Nitz M, Williams P, Schwartz MA, Theodorescu D. Abstract 5130: Src and Caveolin-1 reciprocally regulate metastasis via Rho Kinase Cancer Research. 70: 5130-5130. DOI: 10.1158/1538-7445.Am10-5130 |
0.725 |
|
| 2010 |
Thomas S, Harding MA, Wu Z, Overdevest J, Theodorescu D. Abstract 5080: CD24 expression by prostate and bladder cancer cells is induced by hypoxia and promotes tumor growth and metastasis Cancer Research. 70: 5080-5080. DOI: 10.1158/1538-7445.Am10-5080 |
0.705 |
|
| 2010 |
Smith SC, Baras AS, Wang H, Owens CR, Theodorescu D. Abstract 5063: Signatures of Ral GTPase status define key clinicopathologic characteristics and outcomes in cancer Cancer Research. 70: 5063-5063. DOI: 10.1158/1538-7445.Am10-5063 |
0.513 |
|
| 2010 |
Kim Y, Theodorescu D, Lee JK. Abstract 3732: Drug signaling network-based prediction of therapeutic response to anti-cancer agents Cancer Research. 70: 3732-3732. DOI: 10.1158/1538-7445.Am10-3732 |
0.414 |
|
| 2010 |
Wang H, Wang X, Owens C, Chandra N, Conaway MR, Brautigan DL, Theodorescu D. Abstract 311: Phosphorylation of RalB by PKC regulates its intracellular distribution and promotion of bladder tumor growth Cancer Research. 70: 311-311. DOI: 10.1158/1538-7445.Am10-311 |
0.384 |
|
| 2010 |
Nitz MD, Harding MA, Theodorescu D. Abstract 3090: RREB1 is necessary for the proliferation of bladder cancer cell lines Cancer Research. 70: 3090-3090. DOI: 10.1158/1538-7445.Am10-3090 |
0.476 |
|
| 2010 |
Pollard C, Thomas S, Harding MA, Theodorescu D. Abstract 3082: A paradoxical suppressive role for Src in urothelial carcinoma Cancer Research. 70: 3082-3082. DOI: 10.1158/1538-7445.Am10-3082 |
0.515 |
|
| 2010 |
Cho S, Theodorescu D, Lee JK, Laurent-Puig P. Abstract 2700: In vitro-based COXEN biomarker model predicts outcome in metastatic colorectal cancer patients treated with cetuximab Cancer Research. 70: 2700-2700. DOI: 10.1158/1538-7445.Am10-2700 |
0.393 |
|
| 2010 |
Said NA, Theodorescu D. Abstract 2280: Endothelin axis in bladder cancer metastasis Cancer Research. 70: 2280-2280. DOI: 10.1158/1538-7445.Am10-2280 |
0.448 |
|
| 2009 |
Steeg PS, Anderson RL, Bar-Eli M, Chambers AF, Eccles SA, Hunter K, Itoh K, Kang Y, Matrisian LM, Sleeman JP, Theodorescu D, Thompson EW, Welch DR. An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4529. PMID 25278743 DOI: 10.1158/1078-0432.Ccr-09-1363 |
0.334 |
|
| 2009 |
Dong L, Bard AJ, Richards WG, Nitz MD, Theodorescu D, Bueno R, Gordon GJ. A gene expression ratio-based diagnostic test for bladder cancer. Advances and Applications in Bioinformatics and Chemistry : Aabc. 2: 17-22. PMID 21918612 DOI: 10.2147/AABC.S4148 |
0.337 |
|
| 2009 |
Ehdaie B, Smith SC, Theodorescu D. Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 3: S232-6. PMID 20019992 DOI: 10.5489/Cuaj.1204 |
0.44 |
|
| 2009 |
Said N, Theodorescu D. Pathways of metastasis suppression in bladder cancer. Cancer Metastasis Reviews. 28: 327-33. PMID 20013033 DOI: 10.1007/S10555-009-9197-4 |
0.458 |
|
| 2009 |
Havaleshko DM, Smith SC, Cho H, Cheon S, Owens CR, Lee JK, Liotta LA, Espina V, Wulfkuhle JD, Petricoin EF, Theodorescu D. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia (New York, N.Y.). 11: 1185-93. PMID 19881954 DOI: 10.1593/Neo.09898 |
0.396 |
|
| 2009 |
Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, Dinney CP. Bladder cancer: narrowing the gap between evidence and practice. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5680-4. PMID 19858384 DOI: 10.1200/Jco.2009.23.6901 |
0.396 |
|
| 2009 |
Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, Theodorescu D, Lee JK. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Research. 69: 8302-9. PMID 19843853 DOI: 10.1158/0008-5472.Can-09-0798 |
0.445 |
|
| 2009 |
Pollard C, Nitz M, Baras A, Williams P, Moskaluk C, Theodorescu D. Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. The American Journal of Pathology. 175: 1824-30. PMID 19815704 DOI: 10.2353/Ajpath.2009.090155 |
0.361 |
|
| 2009 |
Ehdaie B, Stukenborg GJ, Theodorescu D. Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer. The Journal of Urology. 182: 1482-7. PMID 19683766 DOI: 10.1016/J.Juro.2009.06.043 |
0.301 |
|
| 2009 |
Slack-Davis JK, Hershey ED, Theodorescu D, Frierson HF, Parsons JT. Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model Molecular Cancer Therapeutics. 8: 2470-2477. PMID 19671741 DOI: 10.1158/1535-7163.Mct-09-0262 |
0.476 |
|
| 2009 |
Schiffer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, Geschwend JE, Neuhaus J, Stolzenburg JU, Conaway MR, Mischak H, Theodorescu D. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4935-43. PMID 19602546 DOI: 10.1158/1078-0432.Ccr-09-0226 |
0.337 |
|
| 2009 |
Said N, Frierson HF, Chernauskas D, Conaway M, Motamed K, Theodorescu D. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene. 28: 3487-98. PMID 19597474 DOI: 10.1038/Onc.2009.205 |
0.412 |
|
| 2009 |
Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, Theodorescu D. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proceedings of the National Academy of Sciences of the United States of America. 106: 5807-12. PMID 19321744 DOI: 10.1073/Pnas.0810094106 |
0.465 |
|
| 2009 |
Moissoglu K, McRoberts KS, Meier JA, Theodorescu D, Schwartz MA. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Research. 69: 2838-44. PMID 19276387 DOI: 10.1158/0008-5472.Can-08-1397 |
0.339 |
|
| 2009 |
Overdevest JB, Theodorescu D, Lee JK. Utilizing the molecular gateway: the path to personalized cancer management. Clinical Chemistry. 55: 684-97. PMID 19246616 DOI: 10.1373/Clinchem.2008.118554 |
0.66 |
|
| 2009 |
Smith SC, Nicholson B, Nitz M, Frierson HF, Smolkin M, Hampton G, El-Rifai W, Theodorescu D. Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. The American Journal of Pathology. 174: 371-9. PMID 19147813 DOI: 10.2353/ajpath.2009.080538 |
0.369 |
|
| 2009 |
Smith SC, Theodorescu D. The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. Urologic Oncology. 27: 42-7. PMID 19111797 DOI: 10.1016/j.urolonc.2008.04.012 |
0.384 |
|
| 2009 |
Wu Z, Cho H, Hampton GM, Theodorescu D. Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia (New York, N.Y.). 11: 66-76. PMID 19107233 DOI: 10.1593/Neo.81048 |
0.453 |
|
| 2009 |
Thomas CY, Dunlap‐Brown M, Brautigan DL, Theodorescu D. Abstract B102: Zibotentan (ZD4054), a specific antagonist of the endothelin A receptor, suppresses the metastatic phenotype of bladder cancer cells in vivo Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B102 |
0.438 |
|
| 2008 |
Schwartz MA, McRoberts K, Coyner M, Andarawewa KL, Frierson HF, Sanders JM, Swenson S, Markland F, Conaway MR, Theodorescu D. Integrin agonists as adjuvants in chemotherapy for melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6193-7. PMID 18829498 DOI: 10.1158/1078-0432.Ccr-08-1285 |
0.334 |
|
| 2008 |
Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene. 27: 6679-89. PMID 18724390 DOI: 10.1038/Onc.2008.264 |
0.491 |
|
| 2008 |
Williams PD, Lee JK, Theodorescu D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia (New York, N.Y.). 10: 838-46. PMID 18670642 DOI: 10.1593/Neo.08432 |
0.401 |
|
| 2008 |
Ehdaie B, Theodorescu D. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert Review of Anticancer Therapy. 8: 1103-10. PMID 18588455 DOI: 10.1586/14737140.8.7.1103 |
0.397 |
|
| 2008 |
Jones RA, Taylor AG, Bourguignon C, Steeves R, Fraser G, Lippert M, Theodorescu D, Mathews H, Kilbridge KL. Family interactions among African American prostate cancer survivors. Family & Community Health. 31: 213-20. PMID 18552602 DOI: 10.1097/01.Fch.0000324478.55706.Fe |
0.374 |
|
| 2008 |
Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. The Prostate. 68: 935-44. PMID 18386291 DOI: 10.1002/Pros.20745 |
0.372 |
|
| 2008 |
Nitz MD, Harding MA, Theodorescu D. Invasion and metastasis models for studying RhoGDI2 in bladder cancer. Methods in Enzymology. 439: 219-33. PMID 18374168 DOI: 10.1016/S0076-6879(07)00417-X |
0.473 |
|
| 2008 |
Smalley DM, Sheman NE, Nelson K, Theodorescu D. Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. Journal of Proteome Research. 7: 2088-96. PMID 18373357 DOI: 10.1021/Pr700775X |
0.444 |
|
| 2008 |
Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1478-86. PMID 18316572 DOI: 10.1158/1078-0432.Ccr-07-1593 |
0.31 |
|
| 2008 |
Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nature Clinical Practice. Oncology. 5: 206-19. PMID 18253104 DOI: 10.1038/Ncponc1066 |
0.438 |
|
| 2008 |
Schiffer E, Mischak H, Theodorescu D, Vlahou A. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World Journal of Urology. 26: 67-74. PMID 18175124 DOI: 10.1007/S00345-007-0234-Z |
0.424 |
|
| 2008 |
Ehdaie B, Stukenborg G, Theodorescu D. Patients With Renal Transplant Or End-Stage Renal Disease Present With More Advanced Bladder Cancer The Journal of Urology. 179: 327-327. DOI: 10.1016/S0022-5347(08)60957-X |
0.304 |
|
| 2007 |
Bigler D, Gioeli D, Conaway MR, Weber MJ, Theodorescu D. Rap2 regulates androgen sensitivity in human prostate cancer cells. The Prostate. 67: 1590-9. PMID 17918750 DOI: 10.1002/Pros.20644 |
0.389 |
|
| 2007 |
Harding MA, Theodorescu D. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urologic Oncology. 25: 401-6. PMID 17826660 DOI: 10.1016/J.Urolonc.2007.05.006 |
0.439 |
|
| 2007 |
Herlevsen MC, Theodorescu D. Mass spectroscopic phosphoprotein mapping of Ral binding protein 1 (RalBP1/Rip1/RLIP76). Biochemical and Biophysical Research Communications. 362: 56-62. PMID 17706599 DOI: 10.1016/J.Bbrc.2007.07.163 |
0.326 |
|
| 2007 |
Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, Theodorescu D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proceedings of the National Academy of Sciences of the United States of America. 104: 13086-91. PMID 17666531 DOI: 10.1016/J.Juro.2007.10.016 |
0.427 |
|
| 2007 |
Smith SC, Oxford G, Baras AS, Owens C, Havaleshko D, Brautigan DL, Safo MK, Theodorescu D. Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3803-13. PMID 17606711 DOI: 10.1158/1078-0432.Ccr-06-2419 |
0.398 |
|
| 2007 |
Herlevsen M, Oxford G, Owens CR, Conaway M, Theodorescu D. Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes. Molecular Cancer Therapeutics. 6: 1804-13. PMID 17575109 DOI: 10.1158/1535-7163.Mct-06-0372 |
0.35 |
|
| 2007 |
Jones RA, Taylor AG, Bourguignon C, Steeves R, Fraser G, Lippert M, Theodorescu D, Mathews H, Kilbridge KL. Complementary and alternative medicine modality use and beliefs among African American prostate cancer survivors. Oncology Nursing Forum. 34: 359-64. PMID 17573300 DOI: 10.1188/07.Onf.359-364 |
0.356 |
|
| 2007 |
Oxford G, Smith SC, Hampton G, Theodorescu D. Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector. Oncogene. 26: 7143-52. PMID 17496927 DOI: 10.1038/Sj.Onc.1210521 |
0.367 |
|
| 2007 |
Wu Z, McRoberts KS, Theodorescu D. The role of PTEN in prostate cancer cell tropism to the bone micro-environment. Carcinogenesis. 28: 1393-400. PMID 17347137 DOI: 10.1093/Carcin/Bgm050 |
0.419 |
|
| 2007 |
Ehdaie B, Theodorescu D. Organ-sparing techniques for penile cancer: quo vadis? Nature Clinical Practice. Urology. 4: 182-3. PMID 17310235 DOI: 10.1038/Ncpuro0737 |
0.357 |
|
| 2007 |
Havaleshko DM, Cho H, Conaway M, Owens CR, Hampton G, Lee JK, Theodorescu D. Prediction of drug combination chemosensitivity in human bladder cancer. Molecular Cancer Therapeutics. 6: 578-86. PMID 17308055 DOI: 10.1158/1535-7163.Mct-06-0497 |
0.426 |
|
| 2007 |
Herlevsen M, Oxford G, Ptak C, Shabanowitz J, Hunt DF, Conaway M, Theodorescu D. A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer. Biochemical and Biophysical Research Communications. 352: 549-55. PMID 17126809 DOI: 10.1016/J.Bbrc.2006.11.067 |
0.474 |
|
| 2007 |
Thomas CY, Theodorescu D. Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World Journal of Urology. 24: 565-78. PMID 17063322 DOI: 10.1007/S00345-006-0119-6 |
0.42 |
|
| 2007 |
Wu Y, McRoberts K, Berr SS, Frierson HF, Conaway M, Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia Oncogene. 26: 765-773. PMID 16878152 DOI: 10.1038/Sj.Onc.1209835 |
0.487 |
|
| 2007 |
Lee J, Theodorescu D. 1670: A New Approach for Predicting the Chemosensitivity of Human Cancers and its Application to Drug Discovery Journal of Urology. 177: 554-554. DOI: 10.1016/S0022-5347(18)31858-5 |
0.355 |
|
| 2007 |
Smith S, Oxford G, Theodorescu D. 764: Differential Expression of RAL GTPases and their Effectors in Bladder Cancer Journal of Urology. 177: 256-256. DOI: 10.1016/S0022-5347(18)31004-8 |
0.443 |
|
| 2007 |
Ehdaie B, Theodorescu D. Re: Postoperative Nomogram Predicting Risk of Recurrence after Radical Cystectomy for Bladder Cancer European Urology. 52: 281-282. DOI: 10.1016/J.Eururo.2007.04.016 |
0.371 |
|
| 2006 |
Moon K, Theodorescu D. Does saturation biopsy improve prostate cancer detection? Nature Clinical Practice. Urology. 3: 468-9. PMID 16964184 DOI: 10.1038/Ncpuro0552 |
0.387 |
|
| 2006 |
Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer Cancer. 107: 991-998. PMID 16878323 DOI: 10.1002/Cncr.22083 |
0.409 |
|
| 2006 |
Rinker-Schaeffer CW, O'Keefe JP, Welch DR, Theodorescu D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3882-9. PMID 16818682 DOI: 10.1158/1078-0432.Ccr-06-1014 |
0.349 |
|
| 2006 |
Wu Z, Conaway M, Gioeli D, Weber MJ, Theodorescu D. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. The Prostate. 66: 1114-23. PMID 16637073 DOI: 10.1002/Pros.20447 |
0.397 |
|
| 2006 |
Wu Z, Siadaty MS, Riddick G, Frierson HF, Lee JK, Golden W, Knuutila S, Hampton GM, El-Rifai W, Theodorescu D. A novel method for gene expression mapping of metastatic competence in human bladder cancer. Neoplasia (New York, N.Y.). 8: 181-9. PMID 16611411 DOI: 10.1593/Neo.05727 |
0.359 |
|
| 2006 |
Miller NL, Theodorescu D. Status of robotic cystectomy in 2005. World Journal of Urology. 24: 180-7. PMID 16557389 DOI: 10.1007/S00345-006-0066-2 |
0.324 |
|
| 2006 |
Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. The Lancet. Oncology. 7: 230-40. PMID 16510332 DOI: 10.1016/S1470-2045(06)70584-8 |
0.409 |
|
| 2006 |
Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G, Theodorescu D. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Research. 66: 1917-22. PMID 16488989 DOI: 10.1158/0008-5472.Can-05-3855 |
0.436 |
|
| 2006 |
Woolsey J, Bissonette E, Schneider BF, Theodorescu D. Prospective outcomes associated with migration from preoperative to intraoperative planned brachytherapy: a single center report. The Journal of Urology. 172: 2528-31. PMID 15538201 DOI: 10.1097/01.Ju.0000144200.48725.E2 |
0.312 |
|
| 2006 |
Wu Z, Young A, Theodorescu D. 425: PTEN Inhibits Prostate Cancer Cell Migration in the Bone Microenvironment Journal of Urology. 175: 138-139. DOI: 10.1016/S0022-5347(18)32681-8 |
0.391 |
|
| 2006 |
Moon K, Stukenborg GJ, Keim J, Theodorescu D. 213: Pelvic Cancer Incidence after Radiotherapy for Localized Prostate Cancer The Journal of Urology. 175: 70-70. DOI: 10.1016/S0022-5347(18)32480-7 |
0.435 |
|
| 2005 |
Titus B, Frierson HF, Conaway M, Ching K, Guise T, Chirgwin J, Hampton G, Theodorescu D. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Research. 65: 7320-7. PMID 16103083 DOI: 10.1158/0008-5472.Can-05-1403 |
0.444 |
|
| 2005 |
Oxford G, Owens CR, Titus BJ, Foreman TL, Herlevsen MC, Smith SC, Theodorescu D. RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Research. 65: 7111-20. PMID 16103060 DOI: 10.1158/0008-5472.Can-04-1957 |
0.407 |
|
| 2005 |
Titus B, Schwartz MA, Theodorescu D. Rho proteins in cell migration and metastasis. Critical Reviews in Eukaryotic Gene Expression. 15: 103-14. PMID 16022631 DOI: 10.1615/Critreveukaryotgeneexpr.V15.I2.20 |
0.413 |
|
| 2005 |
Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, Ross M, Eltze E, Bettendorf O, Wulfing C, Semjonow A. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis. 26: 2797-808. PMID 15981297 DOI: 10.1002/Elps.200400208 |
0.348 |
|
| 2005 |
Smith SC, Oxford G, Theodorescu D. The promise of gene-expression analysis in bladder cancer: a clinician's guide. Bju International. 95: 874-80. PMID 15794801 DOI: 10.1111/J.1464-410X.2005.05419.X |
0.423 |
|
| 2005 |
Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 8728-34. PMID 15623658 DOI: 10.1158/1078-0432.Ccr-04-0902 |
0.397 |
|
| 2005 |
Koutrouvelis PG, Theodorescu D, Katz S, Lailas N, Hendricks F. Brachytherapy of prostate cancer after colectomy for colorectal cancer: pilot experience. The Journal of Urology. 173: 82-5; discussion 85-. PMID 15592034 DOI: 10.1097/01.JU.0000146043.65229.9B |
0.338 |
|
| 2005 |
Globus T, Theodorescu D, Frierson H, Khromova T, Woolard D. Terahertz spectroscopic characterization of cancer cells Progress in Biomedical Optics and Imaging - Proceedings of Spie. 5692: 233-240. DOI: 10.1117/12.594391 |
0.345 |
|
| 2005 |
Wu Z, Riddick G, Siadaty M, Lee J, Theodorescu D. 1316: Expression Mapping the Evolution of Human Metastatic Bladder Cancer Journal of Urology. 173: 357-358. DOI: 10.1016/S0022-5347(18)35461-2 |
0.409 |
|
| 2005 |
Titus B, Chirgwin J, Guise T, Hampton G, Theodorescu D. 595: The Metastasis Suppressor Gene RhoGDI2 Reduceslung Metastasis in Human Bladder Cancer Via Downregulation of Endothelin 1 Journal of Urology. 173: 163-163. DOI: 10.1016/S0022-5347(18)34835-3 |
0.446 |
|
| 2005 |
Titus B, Oxford G, Owens C, Smith S, Foreman T, Herlevsen M, Theodorescu D. 580: RalA and RalB: Antagonistic Relatives in Bladder Cancer Cell Migration Journal of Urology. 173: 158-159. DOI: 10.1016/S0022-5347(18)34820-1 |
0.451 |
|
| 2005 |
Nicholson B, Wedge S, Conaway M, Theodorescu D. 576: Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer: A Promising Therapeutic Approach Journal of Urology. 173: 157-157. DOI: 10.1016/S0022-5347(18)34816-X |
0.389 |
|
| 2004 |
Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, Theodorescu D. Profiling the evolution of human metastatic bladder cancer. Cancer Research. 64: 7813-21. PMID 15520187 DOI: 10.1158/0008-5472.Can-04-0826 |
0.467 |
|
| 2004 |
Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, Frierson HF, Theodorescu D. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene. 23: 6788-97. PMID 15273733 DOI: 10.1038/Sj.Onc.1207599 |
0.434 |
|
| 2004 |
Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer Clinical Cancer Research. 10: 3800-3806. PMID 15173088 DOI: 10.1158/1078-0432.Ccr-03-0653 |
0.48 |
|
| 2004 |
Makhlouf AA, Krupski TL, Kunkle D, Theodorescu D. The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy Bju International. 93: 271-274. PMID 14764121 DOI: 10.1111/J.1464-410X.2004.04600.X |
0.341 |
|
| 2004 |
Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. Journal of Cellular Biochemistry. 91: 125-50. PMID 14689586 DOI: 10.1002/Jcb.10772 |
0.423 |
|
| 2004 |
Horwitz EM, Uzzo RG, Miller N, Theodorescu D. Brachytherapy for prostate cancer: follow-up and management of treatment failures. The Urologic Clinics of North America. 30: 737-50, viii-ix. PMID 14680311 DOI: 10.1016/S0094-0143(03)00059-4 |
0.337 |
|
| 2004 |
Titus BJ, Nicholson BE, Theodorescu D. 952: Marcks Downregulation is Associated with Loss of Metastatic Phenotype Following Transfection of the Metastasis Suppressor Gene RhoGDI2 in the Metastatic Human Bladder Cancer Cell Line T24T Journal of Urology. 171: 252-252. DOI: 10.1016/S0022-5347(18)38189-8 |
0.447 |
|
| 2003 |
Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. The Journal of Urology. 170: 1987-93. PMID 14532839 DOI: 10.1097/01.Ju.0000088670.02905.78 |
0.468 |
|
| 2003 |
Woolsey J, Miller N, Theodorescu D. Permanent interstitial brachytherapy for prostate cancer: a current review. World Journal of Urology. 21: 209-19. PMID 12920559 DOI: 10.1007/S00345-003-0357-9 |
0.381 |
|
| 2003 |
Theodorescu D, Pollack A. Radiation for prostate cancer issue. World Journal of Urology. 21: 189. PMID 12905007 DOI: 10.1007/S00345-003-0354-Z |
0.376 |
|
| 2003 |
Hall JD, Bissonette EA, Boyd JC, Theodorescu D. Motivations and influences on the use of complementary medicine in patients with localized prostate cancer treated with curative intent: results of a pilot study. Bju International. 91: 603-7. PMID 12699468 DOI: 10.1046/J.1464-410X.2003.04181.X |
0.379 |
|
| 2003 |
Bigler D, Gulding KM, Dann R, Sheabar FZ, Conaway MR, Theodorescu D. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action. Oncogene. 22: 1261-72. PMID 12606954 DOI: 10.1038/Sj.Onc.1206242 |
0.423 |
|
| 2003 |
Nicholson B, Theodorescu D. Molecular therapeutics in prostate cancer. Histology and Histopathology. 18: 275-98. PMID 12507306 DOI: 10.14670/HH-18.275 |
0.304 |
|
| 2003 |
Coblentz TR, Bissonette EA, Williams KR, Theodorescu D. Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients. Prostate Cancer and Prostatic Diseases. 5: 219-25. PMID 12496985 DOI: 10.1038/Sj.Pcan.4500585 |
0.349 |
|
| 2002 |
Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Research. 62: 6418-23. PMID 12438227 |
0.377 |
|
| 2002 |
Nicholson B, Schaefer G, Theodorescu D. Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Reviews. 20: 297-319. PMID 12085968 DOI: 10.1023/A:1015543713485 |
0.399 |
|
| 2002 |
Gildea JJ, Harding MA, Seraj MJ, Gulding KM, Theodorescu D. The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Research. 62: 982-5. PMID 11861368 |
0.312 |
|
| 2002 |
Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D. Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene. 20: 7624-34. PMID 11753640 DOI: 10.1038/Sj.Onc.1204972 |
0.306 |
|
| 2002 |
Krupski T, Harding MA, Herce ME, Gulding KM, Stoler MH, Theodorescu D. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors (Chur, Switzerland). 18: 287-302. PMID 11519827 DOI: 10.3109/08977190109029117 |
0.309 |
|
| 2002 |
Coblentz TR, Theodorescu D. Morbidity of Modified Prophylactic Inguinal Lymphadenectomy for Squamous Cell Carcinoma of the Penis Journal of Urology. 168: 1386-1389. DOI: 10.1016/S0022-5347(05)64455-2 |
0.334 |
|
| 2001 |
Karns LR, Kisielewski A, Gulding KM, Seraj JM, Theodorescu D. Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts. Bmc Biotechnology. 1: 11. PMID 11782290 DOI: 10.1186/1472-6750-1-11 |
0.351 |
|
| 2000 |
Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clinical & Experimental Metastasis. 18: 519-25. PMID 11592309 DOI: 10.1023/A:1011819621859 |
0.435 |
|
| 2000 |
Harding MA, Theodorescu D. Prostate tumor progression and prognosis. interplay of tumor and host factors. Urologic Oncology-Seminars and Original Investigations. 5: 258-264. PMID 11008094 DOI: 10.1016/S1078-1439(00)00073-9 |
0.448 |
|
| 2000 |
Gardner TA, Bissonette EA, Petroni GR, McClain R, Sokoloff MH, Theodorescu D. Surgical postoperative factors affecting length of hospital stay after radical prostatectomy Cancer. 89: 424-430. PMID 10918175 DOI: 10.1002/1097-0142(20000715)89:2<424::Aid-Cncr30>3.0.Co;2-6 |
0.317 |
|
| 2000 |
Gildea JJ, Harding MA, Gulding KM, Theodorescu D. Transmembrane motility assay of transiently transfected cells by fluorescent cell counting and luciferase measurement. Biotechniques. 29: 81-6. PMID 10907081 DOI: 10.2144/00291St02 |
0.306 |
|
| 2000 |
Sheta EA, Harding MA, Conaway MR, Theodorescu D. Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor Journal of the National Cancer Institute. 92: 1065-1073. PMID 10880549 DOI: 10.1093/Jnci/92.13.1065 |
0.322 |
|
| 2000 |
Krupski T, Moskaluk C, Boyd JC, Theodorescu D. A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder. Bju International. 85: 1027-32. PMID 10848689 DOI: 10.1046/J.1464-410X.2000.00676.X |
0.345 |
|
| 2000 |
Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology. 55: 736-42. PMID 10792092 DOI: 10.1016/S0090-4295(99)00597-X |
0.383 |
|
| 2000 |
Gildea JJ, Golden WL, Harding MA, Theodorescu D. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes, Chromosomes & Cancer. 27: 252-63. PMID 10679914 DOI: 10.1002/(Sici)1098-2264(200003)27:3<252::Aid-Gcc5>3.0.Co;2-9 |
0.43 |
|
| 2000 |
Lippert MC, McClain R, Boyd JC, Theodorescu D. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer. 86: 2642-8. PMID 10594859 DOI: 10.1002/(Sici)1097-0142(19991215)86:12<2642::Aid-Cncr8>3.0.Co;2-4 |
0.346 |
|
| 1999 |
Broder SR, Frierson HF, Theodorescu D. Unusual case of non-exophytic invasive penile squamous cell cancer arising from a chronic sinus tract Scandinavian Journal of Urology and Nephrology. 33: 333-335. PMID 10572999 DOI: 10.1080/003655999750017437 |
0.301 |
|
| 1999 |
Harding MA, Theodorescu D. Prognostic markers in localized prostate cancer: from microscopes to molecules. Cancer Metastasis Reviews. 17: 429-37. PMID 10453287 DOI: 10.1023/A:1006137721823 |
0.438 |
|
| 1999 |
Gray M, Petroni GR, Theodorescu D. Urinary function after radical prostatectomy: a comparison of the retropubic and perineal approaches. Urology. 53: 881-90; discussion 8. PMID 10223478 DOI: 10.1016/S0090-4295(99)00071-0 |
0.339 |
|
| 1999 |
Theodorescu D, Frierson HF, Sikes RA. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy Journal of Urology. 161: 1442-1448. PMID 10210369 DOI: 10.1016/S0022-5347(05)68919-7 |
0.378 |
|
| 1999 |
Crane CH, Clark MM, Bissonette EA, Theodorescu D. Prospective evaluation of the effect of ionizing radiation on the bladder tumor-associated (BTA) urine test. International Journal of Radiation Oncology, Biology, Physics. 43: 73-7. PMID 9989516 DOI: 10.1016/S0360-3016(98)00380-0 |
0.324 |
|
| 1999 |
Le CQ, Lippert MC, Theodorescu D. Alternative Medicine Use In Patients Treated With Curative Intent For Localized Prostate Cancer The Journal of Urology. 341. DOI: 10.1097/00005392-199904020-00368 |
0.401 |
|
| 1999 |
Petroni G, Fulmer BR, Theodorescu D. Prospective Assessment Of Voiding Function After Treatment For Localized Prostate Cancer: Comparison Of Interstitial Brachytherapy Vs. Radical Prostatectomy The Journal of Urology. 339. DOI: 10.1097/00005392-199904020-00359 |
0.376 |
|
| 1999 |
Gildea JJ, Golden W, Harding MA, Theodorescu D. The Phenotypic And Cytogenetic Analysis Of T24T, A Highly Tumorigenic Subline Of The Human Bladder Cancer Cell Line T24 The Journal of Urology. 150. DOI: 10.1097/00005392-199904010-00604 |
0.396 |
|
| 1999 |
Sheta EA, Harding MA, Theodorescu D. Vascular Endothelial Growth Factor Is Transcriptionally Regulated By Cell Density In Prostate Cancer Cells The Journal of Urology. 124. DOI: 10.1097/00005392-199904010-00500 |
0.371 |
|
| 1999 |
Bissonette E, Lippert MC, Petroni G, Theodorescu D. Comparison Of Quality Of Life In Patients Treated By Either Radical Prostatectomy Or Brachytherapy For Clinically Localized Prostate Cancer The Journal of Urology. 37. DOI: 10.1097/00005392-199904010-00149 |
0.371 |
|
| 1998 |
Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. International Journal of Cancer. 78: 775-82. PMID 9833772 DOI: 10.1002/(Sici)1097-0215(19981209)78:6<775::Aid-Ijc16>3.0.Co;2-G |
0.455 |
|
| 1997 |
Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. The Journal of Urology. 158: 131-7. PMID 9186339 DOI: 10.1097/00005392-199707000-00040 |
0.416 |
|
| 1997 |
Harding M, Theodorescu D. Molecular markers: their role as prognostic indicators for bladder cancer Current Opinion in Urology. 7: 282-286. DOI: 10.1097/00042307-199709000-00008 |
0.436 |
|
| 1996 |
Theodorescu D. Prostate cancer--our patients' questions. The Journal of Urology. 155: 1661-2. PMID 8627848 DOI: 10.1016/S0022-5347(01)66157-3 |
0.41 |
|
| 1991 |
Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 87: 9047-51. PMID 2247480 DOI: 10.1073/Pnas.87.22.9047 |
0.317 |
|
| 1991 |
Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 88: 6028-32. PMID 2068080 DOI: 10.1073/Pnas.88.14.6028 |
0.346 |
|
| Show low-probability matches. |